Immunome reports FY2025 net loss $212.4M; cash $653.5M; varegacestat NDA planned Q2 2026

Immunome Inc.

Cash and equivalents $653.5M as of Dec 31, 2025; runway expected into 2028.
Net loss of $212.4M for FY2025; R&D expenses $177.3M.
Phase 3 RINGSIDE met primary endpoint: 84% reduction in risk of progression or death (HR=0.16, p<0.0001).
NDA submission for varegacestat in desmoid tumors planned for Q2 2026.
Three IND submissions for solid tumor ADCs (IM-1617, IM-1340, IM-1335) planned in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.